Key result
Mitral regurgitation is linked to ~$10,600 higher first-year inpatient charges.
Why the study?
Mitral regurgitation is the most common valvular disease in the United States and increases the risk of death and hospitalization, but its economic burden in the United States was not known.
Do surgical or transcatheter interventions for mitral regurgitation reduce long-term inpatient healthcare charges compared with medical management?
Cohort (n=1,221,173)
Yes
Do surgical or transcatheter interventions for mitral regurgitation reduce long-term inpatient healthcare charges compared with medical management?
Although surgical and transcatheter interventions for mitral regurgitation incur higher upfront costs in the index year, they are associated with reduced inpatient charges in the subsequent years compared with medical management alone.
MR costs may inform resource planning in hospitalized patients; extends observational burden data but leaves open intervention cost offsets.
BACKGROUND: Mitral regurgitation (MR) is the most common valvular disease in the United States and increases the risk of death and hospitalization. The economic burden of MR in the United States is not known. METHODS AND RESULTS: We analyzed inpatient hospitalization data from the 1 221 173 Maryland residents who had any in-state admissions from October 1, 2015, to September 30, 2019. We assessed the total charges for patients without MR and for patients with MR who underwent medical management, transcatheter mitral valve repair or replacement, or surgical mitral valve repair or replacement. During the study period, 26 076 inpatients had a diagnosis of MR. Compared with patients without MR, these patients had more comorbidities and higher inpatient mortality. Patients with medically managed MR incurred average total charges of $23 575 per year; MR was associated with $10 559 more in charges per year and an incremental 3.1 more inpatient days per year as compared with patients without MR. Both surgical mitral valve repair or replacement and transcatheter mitral valve repair or replacement were associated with higher charges as compared with medical management during the year of intervention ($47 943 for surgical mitral valve repair or replacement and $63 108 for transcatheter mitral valve repair or replacement). Annual charges for both groups were significantly lower as compared with medical management in the second and third years postintervention. CONCLUSIONS: MR is associated with higher mortality and inpatient charges. Patients who undergo surgical or transcatheter intervention incur lower charges compared with medically managed MR patients in the years after the procedure.
No takes yet. Share an insight, caveat, or question.
Zinoviev et al. (2024) conducted a cohort in Mitral regurgitation (n=1,221,173). Mitral regurgitation vs. No mitral regurgitation was evaluated on Incremental inpatient hospital charges in the first year (MD 10559, 95% CI 9879-11239, p=<0.001). Mitral regurgitation was associated with a significant adjusted incremental inpatient charge of $10,559 in the first year compared to patients without mitral regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: